|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's range||61.00 - 61.00|
|52-week range||59.90 - 84.04|
|Beta (5Y monthly)||0.98|
|PE ratio (TTM)||17.66|
|Forward dividend & yield||1.40 (2.30%)|
|Ex-dividend date||13 May 2022|
|1y target est||N/A|
HONG KONG, May 12, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care’ campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America.
Fresenius Medical's (FMS) first-quarter earnings benefit from strong performance across all the geographic regions and segments.
German healthcare group Fresenius's first-quarter profit exceeded market expectations on Wednesday, driven by growth in its generic infusion drugs unit in emerging markets. However, the group warned cost inflation and supply chain disruptions were likely to increase this year, fuelled by Russia's invasion of Ukraine. Fresenius's businesses include the Helios hospital chain, drugmaker Kabi, medical services firm Vamed and dialysis specialist Fresenius Medical Care (FMC).